|Slideshows|July 11, 2019

Special Report Countdown: Practice Management

A collection of tools and best practices by psychiatrists who have "been there" to help you develop and structure your own rewarding practice.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

ByJames M. Swanson, PhD,Anthony A. Grace, PhD

November 21st 2025

The Future of ADHD Care: Redefining Adult Diagnosis and Treatment

ByCorina Weir, PhD

November 20th 2025

ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality

ByDavid W. Goodman, MD

November 19th 2025

ADHD: Correcting Careless Myths

ByStephen Mateka, DO

November 18th 2025

Poll: Has the Shortage of IV Ativan Impacted Your Practice?

ByPsychiatric Times Editors

November 5th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Special Report Countdown: Practice Management

Newsletter

Related Content

Tolerance to Stimulant Medications in the Treatment of Children With ADHD

The Future of ADHD Care: Redefining Adult Diagnosis and Treatment

ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality

ADHD: Correcting Careless Myths

Poll: Has the Shortage of IV Ativan Impacted Your Practice?

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

The Epstein Files, the Abuse of Women, and Psychiatry

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

The Hybrid Model: Humans & Chatbots Working Together

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD